Alveron Pharma BV
- Biotech or pharma, therapeutic R&D
Alveron Pharma is developing a synthetic drug, OKL-1111, for the rapid treatment of intracranial haemorrhage associated with the use of anticoagulants or platelet inhibitors. The drug has completed a phase 1 clinical trial. Current therapies require a complex, time-consuming regimen resulting in long door to needle times and poor outcomes. Patients are simply treated too late to prevent haematoma expansion and resulting brain injury. OKL-1111's unique profile enables rapid administration that will deliver better patient outcomes.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}